TOTAL VOLUME:

$134.2b

24H VOL:

$126,324,530

24H TRANSACTIONS:

2,388,728,490

OPEN INTEREST:

$1,434,646,834

406,019

Markets across

30,401

events

MATCHED EVENTS:

2,689

PLATFORM COVERAGE:

5

Polymarket:

39%

VS.

Kalshi:

61%

BETA
Dashboards
Tour
All
Financials
Will Pfizer (PFE) beat quarterly earnings?
polymarket

Will Pfizer (PFE) beat quarterly earnings?

Volume:
$8,318

Will Pfizer (PFE) beat quarterly earnings?

 - Polymarket

Will Pfizer (PFE) beat quarterly earnings? - Polymarket

1W

News

Positive

Negative

Neutral

Hover marker for details

Vol.

·

Resolved Aug 4, 2026

Closed: Aug 4, 8:49 AM EST

polymarket

Polymarket

View
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result
polymarket

Will Pfizer (PFE) beat quarterly earnings?

View
100%
Yes 100¢No 0¢
0.1¢
N/A
$8,318
N/A
N/A
N/A
Settled
Yes
Total markets: 1

Description

As of market creation, Pfizer is estimated to release earnings on August 4, 2026. The Street consensus estimate for Pfizer’s non-GAAP EPS for the relevant quarter is $0.68 as of market creation. This market will resolve to "Yes" if Pfizer reports non-GAAP EPS greater than $0.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Pfizer releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Polymarket

As of market creation, Pfizer is estimated to release earnings on August 4, 2026. The Street consensus estimate for Pfizer’s non-GAAP EPS for the relevant quarter is $0.68 as of market creation. This market will resolve to "Yes" if Pfizer reports non-GAAP EPS greater than $0.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Pfizer releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Frequently asked questions

The dashboard tracks the real-time odds and price history of the Pfizer earnings beat market on Polymarket, showing how traders view the likelihood of Pfizer beating its quarterly earnings expectations. It also displays current volume of $8,318 and 24-hour volume of $229, giving insight into market activity and interest as the earnings release approaches.

Currently, this market reflects a strong expectation of an earnings beat, contrasting with some analyst forecasts that present a more balanced view. While analysts may weigh various metrics like revenue projections and macro factors, traders on Polymarket are pricing in a higher probability of a beat, potentially signaling market sentiment or recent positive signals not yet reflected in mainstream analyst reports.

This market resolves around Aug 4, 2026, with the outcome confirmed once the event is verifiable from credible public reporting. The result will depend on the official earnings release and whether Pfizer’s reported earnings per share exceed analyst consensus estimates, as confirmed by reputable financial news sources.